FDA no deals hammerblow to Belgium's UCB

13 May 2022
ucb_large

A regulatory rebuff in the USA has hampered Brussels, Belgium-based biotech UCB (Euronext: UCB) in its quest to market bimekizumab in plaque psoriasis.

Shares in the company were down nearly a fifth on Friday, after it was revealed that the US Food and Drug Administration had sent the firm a Complete Response Letter (CRL) regarding its submission.

The delay comes on top of a prior deferral, in October 2021, with the FDA at that time blaming COVID-19-related travel restrictions for its inability to reach a verdict.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology